Contraception: Stopping sperm in their tracks

An automated high-throughput platform can screen for molecules that change the motility of sperm cells and their ability to fertilize.
  1. Luke L McGoldrick
  2. Jean-Ju Chung  Is a corresponding author
  1. Department of Cellular and Molecular Physiology, Yale School of Medicine, United States
  2. Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, United States

From 2010 to 2014, about 44% of pregnancies worldwide were unplanned, and over half of these ended in abortion in both developed and developing countries (Bearak et al., 2018). Moreover, these terminations frequently result in the death of women in some regions of the world (Ganatra et al., 2017; WHO, 2011). These statistics confirm the need to make effective family planning more widely available to those who want to adopt it, as this brings positive outcomes to women, families, countries and the environment (Starbird et al., 2016).

Precursors to the modern condom were used in ancient Egypt, and hormone-based female oral contraceptives have been used since the middle of the twentieth century (Khan et al., 2013; Dhont, 2010). Today, most contraceptives are for use by women. Traditional male options include condoms, which are only partially effective, and vasectomies, which men may be hesitant to get because they cannot always be reversed (Manetti and Honig, 2010; Gava and Meriggiola, 2019). There is therefore a need for new male contraceptives, with sperm being an obvious target.

Sperm cells are equipped with a tail-like structure that allows them to be motile and to travel through the female reproductive tract to reach the egg. There, they undergo the acrosome reaction: this involves the sperm cell releasing digestive enzymes that allow it to come into close contact and fuse with an egg. Successful fertilization requires both motility and a successful acrosome reaction, so targeting and disrupting these processes is a good strategy to develop effective male contraceptives.

Now, in eLife, Franz Gruber, Zoe Johnston, Christopher Barratt and Paul Andrews at the University of Dundee report having developed a new screening platform to evaluate the effects of small molecules on the motility of sperm cells and their ability to go through the acrosome reaction (Gruber et al., 2020). The team used a collection of about 12,000 clinical or preclinical small molecules for which human safety data are already available.

To evaluate the effect these molecules have on sperm motility, a robotics system was used to incubate each small molecule with separate batches of sperm for 10 minutes (Figure 1); the cells were then imaged using a camera with a high frame rate to capture motion. In total, 63 candidates were identified as reducing motility by 15% or more, with 29 being confirmed when retested. Some of the hits were promising, such as Disulfiram and KF-4939. Disulfiram has been used to treat alcohol dependency and is known to dampen sperm motility (Lal et al., 2016). KF-4939 is thought to inhibit platelet aggregation factors, which have already been used in male infertility treatments to improve sperm motility (Roudebush et al., 2004). The experiment also highlighted a large number of small molecules that increase, rather than decrease, sperm motility: these molecules need to be investigated further as they could be used to treat infertility.

Automated targeting of sperm motility and acrosome reaction with small molecules.

Sperm are robotically allocated into wells (~10,000 cells/well) in a 384-well plate (top left); each well contains a different small molecule at a concentration of ~6 μM. The insets show KF-4939, an anti-platelet agent, binding to sperm cells. After incubation with the small molecules, sperm motility is imaged and assessed (middle left). Subsequently, the same sperm are mixed with two tags, peanut agglutinin (PNA; green) and propidium iodide (Pi; red), that emit fluorescence when attached to cells. Sperm were analyzed with a technique called flow cytometry (top right): PNA binding to a sperm cell indicates that the cell has undergone the acrosome reaction, while Pi only binds to dead cells. Most sperm cells do not bind to PNA or Pi, some bind to one but not the other, and some bind to both (bottom right).

To improve the efficiency of the screen, the same cells that had been assessed for motility were also examined for the acrosome reaction. Two fluorescent tags, called peanut agglutinin and propidium iodide, helped to detect sperm cells that had gone through the reaction after being exposed to the small molecules. Peanut agglutinin only binds to the heads of sperm cells that have undergone the acrosome reaction, and propidium iodide exclusively attaches to dead cells. An automated technique called flow cytometry was used to record whether the tags were bound to a given cell, therefore measuring the percentage of live cells that had undergone the acrosome reaction after being exposed to the small molecules. However, all nine hits proved to be false positives as the small molecules themselves were fluorescent, highlighting a need to carry on such screenings while being wary of artefacts.

The high-throughput screening platform developed by Gruber et al. has the potential to make important contributions to the search for contraceptives and male infertility drugs. This work only examined one collection of molecules, and two sperm parameters, motility and acrosome reaction. Going forward, it would be interesting to apply this platform to target other aspects of sperm biology that are critical for fertilization, such as hyperactivated motility (when sperm cells vigorously and asymmetrically wag their tail-like structures to enter the egg), or the binding of sperm cells to specific egg proteins.

References

    1. Dhont M
    (2010) History of oral contraception
    The European Journal of Contraception & Reproductive Health Care 15:S12–S18.
    https://doi.org/10.3109/13625187.2010.513071
    1. Gava G
    2. Meriggiola MC
    (2019) Update on male hormonal contraception
    Therapeutic Advances in Endocrinology and Metabolism 10:204201881983484.
    https://doi.org/10.1177/2042018819834846

Article and author information

Author details

  1. Luke L McGoldrick

    Luke L McGoldrick is in the Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, United States

    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8310-7502
  2. Jean-Ju Chung

    Jean-Ju Chung is in the Department of Cellular and Molecular Physiology, Yale School of Medicine, New Haven, United States

    For correspondence
    jean-ju.chung@yale.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8018-1355

Publication history

  1. Version of Record published: February 27, 2020 (version 1)

Copyright

© 2020, McGoldrick and Chung

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,699
    Page views
  • 125
    Downloads
  • 0
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Luke L McGoldrick
  2. Jean-Ju Chung
(2020)
Contraception: Stopping sperm in their tracks
eLife 9:e55396.
https://doi.org/10.7554/eLife.55396

Further reading

    1. Cell Biology
    2. Developmental Biology
    Eunjin Cho, Xiangguo Che ... Tae-Hoon Lee
    Research Article

    Peroxiredoxin 5 (Prdx5) is involved in pathophysiological regulation via the stress-induced cellular response. However, its function in the bone remains largely unknown. Here, we show that Prdx5 is involved in osteoclast and osteoblast differentiation, resulting in osteoporotic phenotypes in Prdx5 knockout (Prdx5Ko) male mice. To investigate the function of Prdx5 in the bone, osteoblasts were analyzed through immunoprecipitation (IP) and liquid chromatography combined with tandem mass spectrometry (LC–MS/MS) methods, while osteoclasts were analyzed through RNA-sequencing. Heterogeneous nuclear ribonucleoprotein K (hnRNPK) was identified as a potential binding partner of Prdx5 during osteoblast differentiation in vitro. Prdx5 acts as a negative regulator of hnRNPK-mediated osteocalcin (Bglap) expression. In addition, transcriptomic analysis revealed that in vitro differentiated osteoclasts from the bone marrow-derived macrophages of Prdx5Ko mice showed enhanced expression of several osteoclast-related genes. These findings indicate that Prdx5 might contribute to the maintenance of bone homeostasis by regulating osteoblast differentiation. This study proposes a new function of Prdx5 in bone remodeling that may be used in developing therapeutic strategies for bone diseases.

    1. Developmental Biology
    Greta Rossi, Gabriele Ordazzo ... Vania Broccoli
    Research Article Updated

    Wolfram syndrome 1 (WS1) is a rare genetic disorder caused by mutations in the WFS1 gene leading to a wide spectrum of clinical dysfunctions, among which blindness, diabetes, and neurological deficits are the most prominent. WFS1 encodes for the endoplasmic reticulum (ER) resident transmembrane protein wolframin with multiple functions in ER processes. However, the WFS1-dependent etiopathology in retinal cells is unknown. Herein, we showed that Wfs1 mutant mice developed early retinal electrophysiological impairments followed by marked visual loss. Interestingly, axons and myelin disruption in the optic nerve preceded the degeneration of the retinal ganglion cell bodies in the retina. Transcriptomics at pre-degenerative stage revealed the STAT3-dependent activation of proinflammatory glial markers with reduction of the homeostatic and pro-survival factors glutamine synthetase and BDNF. Furthermore, label-free comparative proteomics identified a significant reduction of the monocarboxylate transport isoform 1 (MCT1) and its partner basigin that are highly enriched on retinal glia and myelin-forming oligodendrocytes in optic nerve together with wolframin. Loss of MCT1 caused a failure in lactate transfer from glial to neuronal cell bodies and axons leading to a chronic hypometabolic state. Thus, this bioenergetic impairment is occurring concurrently both within the axonal regions and cell bodies of the retinal ganglion cells, selectively endangering their survival while impacting less on other retinal cells. This metabolic dysfunction occurs months before the frank RGC degeneration suggesting an extended time-window for intervening with new therapeutic strategies focused on boosting retinal and optic nerve bioenergetics in WS1.